Stockreport

RGNX's Inadequate Risk Disclosures Allegedly Cost Investors $2.40/Share: Levi & Korsinsky, LLP

REGENXBIO Inc.  (RGNX) 
Last regenxbio inc. earnings: 2/26 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.regenxbio.com
PDF Disclosure Under Scrutiny: Were REGENXBIO's Risk Warnings About AAV Gene Therapy Adequate? NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky, LLP examines the adequacy of R [Read more]